Firuglipel is an orally available and selective agonist of GPR119.

Firuglipel increases intracellular cAMP in a concentration-dependent manner in rat, human, and mouse GPR119-expressing Chinese hamster ovary (CHO)-K1 cells (EC50: 51.5, 98.4, and 108.1 nM, respectively). Firuglipel has no effect on intracellular cAMP in pcDNA3.1/CHO-K1 cells.

Firuglipel (1-30 mg/kg) upregulates glucagon-like peptide-1. It also enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats.

1371591-51-3

C25H26FN3O5

467.49

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years